CGT commercial trajectories are set years before approval — and every development decision is an access decision.
Feature|Articles|August 16, 2024
- Pharmaceutical Executive: July/August 2024
- Volume 44
- Issue 7/8
Divergent Paths: Pharm Exec Profiles Five Recent Drug Launches
Pharm Exec’s latest sampling of notable biopharma brand approvals and launches all have unique stories to tell—from the winding journeys to innovative “firsts” to new momentum for milestones to come.
Advertisement
Follow the links below to read about each product:
Articles in this issue
about 2 years ago
Pharmaceutical Executive: July/August 2024 Issue (PDF)about 2 years ago
An AI Pulse Checkabout 2 years ago
A Promising Option: Exxuaabout 2 years ago
Opening the Door: Omvohabout 2 years ago
'Marked’ for Stardom?: Truqapabout 2 years ago
Branching Off: Wegovyabout 2 years ago
A Formidable First: Winrevairabout 2 years ago
The Future of Launch Excellence is Generative AIabout 2 years ago
From Potential to Value: Carving a Slice of the CGT ‘PIE'about 2 years ago
Big Bets, Bold StepsAdvertisement
Related to this article
Pharma has digitized nearly everything — but contract management remains fragmented, creating compliance risk and slowing execution across the enterprise.
Lisata Therapeutics acquires Marea Therapeutics and secures $225 million in concurrent financing, while mAbxience and Sandoz partner to develop and globally commercialize an emicizumab biosimilar.
Former U.S. Representative Joe Cunningham (D-SC), spokesperson, Pharmaceutical Reform Alliance. dismisses the pharmaceutical industry's innovation argument against MFN pricing.
Inovalon's Jen Lamppa on why inaccurate self-reported data is clinical trial enrollment's costliest problem — and how RWD fixes it.
Five major pharma stories in one day — Novo's rebrand and AI bets, Bayer's 30-year CKD first, GSK's T-cell engager, and Sanofi's portfolio exit.
Former U.S. Representative Joe Cunningham (D-SC), spokesperson, Pharmaceutical Reform Alliance, touches on what he sees as the most realistic path to making MFN pricing permanent.
Novo partners with Anthropic to deploy Claude for targeted drug discovery workflows and AI-driven software development.
Advertisement
Advertisement
Trending on PharmExec
1
M&A Roundup: Lisata Therapeutics Acquires Marea Therapeutics, mAbxience Enters Collaboration with Sandoz
2
Pharmaceutical Executive Daily: FDA Approves Fayuvi
3
The Battle to Own the GLP-1 Patient Journey
4
FDA Approves Fayuvi for Pediatric Patients with Sanfilippo Syndrome Type A
5